Quarterly Result13 May 2025, 07:44 pm
Metropolis Healthcare Reports 26% Normalised PAT Growth for Full Year FY2024-25 and 24% in Q4FY25
AI Summary
Metropolis Healthcare, India's second-largest pathology laboratory chain, announced its audited consolidated financial results for the quarter ended March 31, 2025 (FY25 and Q4FY25). The company reported a Normalised PAT Growth of 26% for the full year and 24% in Q4FY25. Metropolis achieved double-digit revenue growth at 12% YoY for FY2024-25 and 10% YoY in Q4FY25, driven by consistent volume expansion. TruHealth and Specialty diagnostics led as the fastest-growing segments. The revenue growth contribution from Tier III cities stood at 18% in FY25.
Key Highlights
- Metropolis records revenue of INR 1,331 Crore in FY25 and INR 345 Crore in Q4FY25.
- Patient volume grew by 6% YoY and Test Volume grew by 7% in FY25.
- B2C revenues saw a robust 17% YoY growth in FY25 and 14% YoY in Q4FY25.
- B2B revenue grew 12% YoY in FY25 and 10% YoY in Q4FY25.
- TruHealth revenue grew 24% YoY with a strong Q4 exit contributing 19% to total revenue.